Cholangio Today

This is an independent initiative not affiliated with the Cholangiocarcinoma Foundation Australia.

Cancer is more than a clinical challenge—it’s an execution problem.
Better insights, understanding, and response = better survival. Sign up now.

Cholangio Today is a patient-led initiative that cuts through the noise to reshape how we understand, prevent, and respond to cancer—starting now—while keeping you updated with the latest research, clinical trials, strategies, webinars, and group sessions as they become available.

Cancer is complex. Survival shouldn’t be.

Cholangio Today is a patient-led email newsletter magazine designed to simplify GI and digestive tract cancers—especially bile duct and bile-related cancers.

It helps you cut through the noise, act with clarity, and drive better outcomes. Each edition connects the big picture to the practical details—so patients, caregivers, and medical teams can engage more effectively at every stage of the journey.

Built on big thinking, bold innovation, and decisive execution, Cholangio Today breaks down barriers, sparks ideas, and opens new opportunities for those facing the toughest cancers.

Whether you’re navigating a diagnosis or working to improve outcomes, Cholangio Today delivers insight, clarity, and strategy—straight from the front lines. It ensures we extract the most from today’s opportunities while driving toward breakthrough delta moments—where bold, emerging research reaches the patients at the coalface of this battle, today.

Why Sign Up?

  • Survival isn’t just about treatment—it’s about execution.
  • You don’t have time for complexity. We simplify what matters.
  • We respect evidence-based medicine—but we also push boundaries to explore what’s next.
  • Real-world insights from a patient who’s been in the fight—not just theory.

What You Get

  • Straightforward, high-impact insights on GI and digestive tract cancers
  • Clarity, not confusion—understand what’s real and what’s possible
  • Practical, no-nonsense strategies to improve response and survival

Who It’s For

  • Patients who want to actively engage in their survival
  • Caregivers who need clarity and real answers
  • Medical teams looking to align with patient-driven insights that go beyond standard practice

Steve Holmes

Founder, CancerDelt∆ | Stage 4 Bile Duct Cancer Survivor | Founder, Cholangiocarcinoma Foundation Australia

Steve Holmes
Founder, CancerDelt∆ | Stage 4 Bile Duct Cancer Survivor | Founder, Cholangiocarcinoma Foundation Australia

Steve Holmes is not a doctor and does not hold a medical or scientific degree. He is a patient who has walked the talk of the best minds in cancer science—reversing a late-stage, stage 4 diagnosis through a breakthrough made possible by the work of Nobel Laureates Prof. James Allison and Prof. Tasuku Honjo, pioneers of checkpoint inhibitor therapy.

Steve now leads a team of top innovators behind CancerDelt∆, a bold initiative re-engineering how cancer is understood, prevented, and responded to—and also leads the Cholangiocarcinoma Foundation Australia, turning cutting-edge knowledge into actionable tools, strategies, and support systems for patients, caregivers, and the medical community.

His insights are grounded in lived experience, research collaborations, and significant global patient mentorship—working shoulder to shoulder from the front lines of this disease to the halls of healthcare, the labs of science, and the corridors of government.

The views expressed are his own and do not necessarily reflect those of the Cholangiocarcinoma Foundation Australia.